Metabolomic and Genetic Interactions in Age-Related Macular Degeneration
年龄相关性黄斑变性的代谢组学和遗传相互作用
基本信息
- 批准号:8576080
- 负责人:
- 金额:$ 46.8万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-09-01 至 2018-07-31
- 项目状态:已结题
- 来源:
- 关键词:AccountingAgeAge related macular degenerationAmino AcidsAngiogenesis InhibitorsBiological MarkersBlindnessChronic DiseaseClinicClinicalDataDatabasesDeveloped CountriesDevelopmentDiabetes MellitusDiseaseDisease OutcomeDisease ProgressionElderlyExposure toExudative age-related macular degenerationEyeFoodGenesGeneticGenetic PolymorphismGenetic VariationGenotypeGoalsHealthHeart failureIndividualInstitutesInvestigationKnowledgeLinkLiquid ChromatographyLiquid substanceMass Spectrum AnalysisMeasurementMeasuresMetabolicMetabolic PathwayMetabolismMetabolite InteractionMethodologyMethodsMolecularMonitorOutcomeParkinson DiseasePathogenesisPathway interactionsPatientsPeptidesPharmaceutical PreparationsPlasmaPopulationPositioning AttributeRecruitment ActivityRelianceResolutionRiskRisk AssessmentRisk FactorsSamplingSmokingStagingTestingTherapeutic InterventionTissuesToxinTreatment EfficacyTyrosineUnited StatesUniversitiesWorkbasecase controlcohortdietary supplementsdisorder riskgenetic profilinggenetic variantimprovedinsightliquid chromatography mass spectrometrymembermetabolomicsnon-geneticprospectivepublic health relevanceresponsetoxin metabolismtreatment response
项目摘要
PROJECT SUMMARY
Despite recent advances in treatment, age-related macular degeneration (AMD) remains the leading cause of
irreversible blindness in the elderly population. A shift in the current therapy paradigm will require more
sensitive methods of identifying patients at greatest risk for disease development, progression, and poor
treatment response. Previously-investigated genetic polymorphisms account for only a portion of AMD risk.
Other factors include not only health risks, such as smoking and exposure to other toxins, but also individual
metabolism of toxins, drugs, dietary supplements, and perhaps even food. Indeed, comprehensive
measurement of metabolites in fluid or tissue has successfully identified risk factors for other chronic diseases,
including heart failure, diabetes, and Parkinson's disease. Nevertheless, metabolism is influenced largely by
genetic factors. Thus, our long-term goal is to develop profiles combining genetic and metabolic factors to
predict disease risk and treatment response in order to improve clinical outcomes for AMD patients. The
objective of this proposal is more focused: to discern metabolic profiles related to AMD pathogenesis and
determine their relationship to AMD-related genetic variants. Our central hypothesis posits that metabolic
profiles combined with genetic variation drive an individual's risk for AMD development, progression, and
response to treatment. Using high-resolution liquid chromatography-mass spectrometry (LC-MS) and
Sequenom-based genotyping, we will test this hypothesis in two established independent cohorts, along with a
new prospective patient cohort recruited from the Vanderbilt Eye Institute. In Aim 1, measuring plasma
metabolites in AMD patients and controls will tell us the metabolic differences between these groups and
between different stages of AMD. These metabolic variances will point to molecules and pathways that are
associated with AMD and could serve as targets for therapeutic intervention. In Aim 2, we will combine these
metabolic profiles with genotypes for known AMD-risk genes to determine how metabolites and gene variants
interact to influence AMD development and progression. This approach will give us molecular insight into the
variability in disease progression among patients. Finally, Aim 3 will prospectively evaluate the impact of
metabolic and genetic profiles on intermediate AMD progression and NVAMD treatment response. Successful
completion of these aims will provide critical knowledge of metabolic changes associated with AMD and will
help identify patients at greatest risk for disease progression and poor treatment response.
项目摘要
尽管最近的治疗进展,但与年龄相关的黄斑变性(AMD)仍然是
老年人口不可逆转的失明。当前治疗范式的转变将需要更多
识别疾病发育,进展和较差风险的患者的敏感方法
治疗反应。以前对遗传多态性的研究仅占AMD风险的一部分。
其他因素不仅包括健康风险,例如吸烟和暴露于其他毒素,还包括个人
毒素,药物,饮食补充剂甚至食物的代谢。确实,全面
在液体或组织中代谢物的测量已成功鉴定出其他慢性疾病的危险因素,
包括心力衰竭,糖尿病和帕金森氏病。然而,新陈代谢在很大程度上受到影响
遗传因素。因此,我们的长期目标是开发将遗传和代谢因素结合到
预测疾病风险和治疗反应,以改善AMD患者的临床结果。这
该提案的目的更加集中:辨别与AMD发病机理和
确定它们与AMD相关遗传变异的关系。我们的中心假设认为代谢
概况与遗传变异相结合驱动个人的AMD发展,进展和
对治疗的反应。使用高分辨率液相色谱 - 质谱法(LC-MS)和
基于序列的基因分型,我们将在两个已建立的独立人群中检验这一假设,
从范德比尔特眼科研究所招募了新的潜在患者队列。在AIM 1中测量等离子体
AMD患者和对照组中的代谢物将告诉我们这些组和
在不同阶段的AMD之间。这些代谢差异将指向分子和途径
与AMD相关,可以作为治疗干预的靶标。在AIM 2中,我们将结合这些
具有针对已知AMD风险基因的基因型的代谢谱,以确定代谢产物和基因变异
相互作用以影响AMD的发展和进展。这种方法将使我们对分子见解
患者疾病进展的差异。最后,AIM 3将前景评估
中间AMD进展和NVAMD治疗反应的代谢和遗传谱。成功的
这些目标的完成将为与AMD相关的代谢变化提供批判性知识,并将
帮助确定患疾病进展和治疗反应不佳的风险最大的患者。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Milam A Brantley其他文献
Milam A Brantley的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Milam A Brantley', 18)}}的其他基金
Proteomics of human vitreous to investigate mechanisms underlying the variability in anti-VEGF treatment response in neovascular AMD patients
人玻璃体蛋白质组学研究新生血管性 AMD 患者抗 VEGF 治疗反应差异的机制
- 批准号:
10507176 - 财政年份:2022
- 资助金额:
$ 46.8万 - 项目类别:
Proteomics of human vitreous to investigate mechanisms underlying the variability in anti-VEGF treatment response in neovascular AMD patients
人玻璃体蛋白质组学研究新生血管性 AMD 患者抗 VEGF 治疗反应差异的机制
- 批准号:
10673722 - 财政年份:2022
- 资助金额:
$ 46.8万 - 项目类别:
Metabolomic and Genetic Interactions in Age-Related Macular Degeneration
年龄相关性黄斑变性的代谢组学和遗传相互作用
- 批准号:
8717668 - 财政年份:2013
- 资助金额:
$ 46.8万 - 项目类别:
Metabolomic and Genetic Interactions in Age-Related Macular Degeneration
年龄相关性黄斑变性的代谢组学和遗传相互作用
- 批准号:
9302786 - 财政年份:2013
- 资助金额:
$ 46.8万 - 项目类别:
Role of GDNF Family Ligands in Photoreceptor Rescue
GDNF 家族配体在光感受器救援中的作用
- 批准号:
7364163 - 财政年份:2005
- 资助金额:
$ 46.8万 - 项目类别:
Role of GDNF Family Ligands in Photoreceptor Rescue
GDNF 家族配体在光感受器救援中的作用
- 批准号:
6858852 - 财政年份:2005
- 资助金额:
$ 46.8万 - 项目类别:
相似国自然基金
基于“肝—眼轴”的枸杞子及其复方防治青少年近视与年龄相关性黄斑变性的功效物质与生物学机制研究
- 批准号:U21A20408
- 批准年份:2021
- 资助金额:260.00 万元
- 项目类别:
基于“肝-眼轴”的枸杞子及其复方防治青少年近视与年龄相关性黄斑变性的功效物质与生物学机制研究
- 批准号:
- 批准年份:2021
- 资助金额:260 万元
- 项目类别:
PGF突变介导的周细胞与内皮细胞crosstalk在湿性年龄相关性黄斑变性中的作用及机制研究
- 批准号:82000898
- 批准年份:2020
- 资助金额:24 万元
- 项目类别:青年科学基金项目
组织病理结构与临床检查对照观察在指导渗出性年龄相关性黄斑变性诊治中的意义研究
- 批准号:81400409
- 批准年份:2014
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
基于多模态医学影像技术的湿性年龄相关性黄斑变性诊断与分析
- 批准号:81371629
- 批准年份:2013
- 资助金额:75.0 万元
- 项目类别:面上项目
相似海外基金
Inhibiting Neovascularization and Subretinal Fibrosis in Neovascular Age-Related Macular Degeneration
抑制新生血管性年龄相关性黄斑变性的新生血管形成和视网膜下纤维化
- 批准号:
10639785 - 财政年份:2023
- 资助金额:
$ 46.8万 - 项目类别:
True Sub-Micron Ocular Diagnostics with Visible Light Optical Coherence Tomography
使用可见光光学相干断层扫描进行真正的亚微米眼部诊断
- 批准号:
10676879 - 财政年份:2020
- 资助金额:
$ 46.8万 - 项目类别:
True Sub-Micron Ocular Diagnostics with Visible Light Optical Coherence Tomography
使用可见光光学相干断层扫描进行真正的亚微米眼部诊断
- 批准号:
10058787 - 财政年份:2020
- 资助金额:
$ 46.8万 - 项目类别: